Study to Advance Understanding of Brown Adipose (Fat) Biology and Its Role in
MELVILLE, N.Y., Sept. 15, 2015 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT"
or the "Company") (OTCQB:BRTX), a life sciences company focused on stem cell-based
therapies, today announced that the Company has entered into a one-year research
collaboration agreement with the University of Pennsylvania. The research is intended to
develop the Company's ThermoStem® Program by advancing the understanding of brown
adipose ("brown fat") biology and its role in metabolic disorders. Brown fat is recognized as
playing a role in caloric burning, as well as potentially regulating glucose and lipid levels.
The research collaboration will focus on studying the epigenetic regulation of brown fat
transcription and metabolism by nuclear receptors and mechanisms related to obesity-associated
insulin resistance and diabetes. It has recently been demonstrated that motif-altering single
nucleotide polymorphisms (SNPs) cause differential PPARg binding associated in elevated HDL
levels and other metabolic syndrome parameters. Understanding the role that SNPs play upon
an individual's genome has the potential to improve the risk/benefit ratio for patients undergoing
antidiabetic therapy, thereby allowing for personalized pharmacogenomics.
The laboratory of Mitchell Lazar, MD, PhD, the Sylvan Eisman Professor of Medicine and
Genetics in the Perelman School of Medicine at the University of Pennsylvania, will work with
BRT to characterize these brown fat cells. Lazar is also Chief of the Division of Endocrinology,
Diabetes, and Metabolism, and the Director of the Institute for Diabetes, Obesity, and Metabolism
"We are excited to collaborate with the Lazar lab at the University of Pennsylvania, one of the top
research facilities studying the transcriptional and epigenomic regulation of metabolism. This
collaboration is expected to provide additional data, including functional studies and
manipulation of cells, for our ThermoStem® Program. We look forward to working with Dr. Lazar
and his team as we advance our cell-based therapy towards clinical trials," said Mark Weinreb,
CEO of the Company.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products and
medical therapies using cell and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of disc/spine disease and metabolic
• Disc/Spine Program: Our lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells),
is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells
collected from the patient's bone marrow. We intend that the product will be used for the nonsurgical
treatment of protruding and bulging lumbar discs in patients suffering from chronic
lumbar disc disease. The treatment involves collecting a patient's own stem cells, culturing and
cryopreserving the cells, and then having a physician inject brtxDISC™ into the patient's
damaged disc in an outpatient procedure. The treatment is intended for patients whose pain has
not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
• Metabolic Program (ThermoStem®): We are developing an allogeneic cell-based therapy to
target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate
brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose
depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in the body may be responsible for additional caloric burning as
well as reduced glucose and lipid levels. Researchers have found that people with higher levels
of brown fat may have a reduced risk for obesity and diabetes. The Company is a party to a
research agreement with Pfizer with regard to the study of brown fat.
This press release contains "forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and such forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties that could cause future
circumstances, events or results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including those set forth in the
Company's Form 10-K filed with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are made as of the
date hereof and the Company undertakes no obligation to update such statements.